Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

54.89
-0.3100-0.56%
Post-market: 54.80-0.0900-0.16%19:52 EDT
Volume:3.10M
Turnover:169.55M
Market Cap:10.61B
PE:144.83
High:54.97
Open:54.95
Low:53.90
Close:55.20
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.24
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.68
PE(LYR):30.49

Loading ...

Sep 10, 2020

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Sep 09, 2020

Major Issues Report

8-K - Current report
Aug 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 04, 2020

Major Issues Report

8-K - Current report
Jul 02, 2020

Major Issues Report

8-K - Current report
Jun 01, 2020

Major Issues Report

8-K - Current report
May 19, 2020

Major Issues Report

8-K - Current report
May 14, 2020

Major Issues Report

8-K - Current report
May 01, 2020

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Apr 29, 2020

Major Issues Report

8-K - Current report
Apr 22, 2020

Major Issues Report

8-K - Current report
Feb 27, 2020

Annual Report

Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 26, 2020

Major Issues Report

Current report, items 2.02 and 9.01
Feb 14, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 10, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 06, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 04, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 03, 2020

Major Issues Report

Current report, item 5.02